�Urodynamix Technologies Ltd. (TSX-V:URO) announced that it has received a non-refundable fiscal contribution from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to help accelerate the development and commercialization of new NIRS technology for the spotting of prostate cancer during the digital rectal scrutiny, or DRE.
Urodynamix's new technology, based on
